This activity is expired and is no longer available for CME credit.


Harnessing Immunological Pathways to Improve the Treatment of Moderate to Severe Crohns Disease

Author(s)/Faculty: William J. Sandborn, MD; Jessica R. Allegretti, MD, MPH; Bruce E. Sands, MD, MS
Release Date: 3/31/2021Expiration Date: 3/30/2022
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
Crohn’s disease (CD) is a chronic, progressive, idiopathic inflammatory disorder that can affect any component of the gastrointestinal tract. Approximately 780,000 individuals in the United States have CD, with the incidence and prevalence increasing worldwide. The ongoing clinical evaluation of emerging therapies with unique mechanisms of action holds promise for a more optimal disease response. Over the past 20 years, biologic agents have redefined the management of moderate to severe CD. Agents that impact not only clinical response and remission but also mucosal healing are now of paramount interest. Available biologic therapies for CD include anti–tumor necrosis factor-α agents, an integrin inhibitor, and interleukin 12/23 inhibitors--all of which are administered either intravenously or subcutaneously. Several oral small-molecule therapies are also under investigation for the treatment of moderate to severe CD, including Janus kinase protein inhibitors. Oral agents that modulate sphingosine 1-phosphate, which guides lymphocyte circulation through secondary lymphoid organs such as the spleen and lymph nodes, are being studied as well. In this CME activity, experts summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for treating moderate to severe CD. The most recent clinical findings on the safety and efficacy of therapies targeting immunological pathways are also evaluated.